{"filing":{"accession_number":"0001683168-26-006077","cik":"0001534525","ticker":"XBIO","company_name":"Xenetic Biosciences, Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"xenetic_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/xenetic_8k.htm"},"events":[{"id":26237,"run_id":23829,"accession_number":"0001683168-26-006077","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (three months ended June 30, 2026). The press release (Exhibit 99.1) reports royalty revenue of approximately $0.7 million, R\u0026D expenses of $0.6 million, G\u0026A expenses of $1.1 million, and a net loss of approximately $0.9 million, along with cash position of $6.5 million. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing results for the three months ended June 30, 2026,\" which is the hallmark of an earnings release event.","company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27278,"accession_number":"0001683168-26-006077","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (three months ended June 30, 2026). The press release (Exhibit 99.1) reports royalty revenue of approximately $0.7 million, R\u0026D expenses of $0.6 million, G\u0026A expenses of $1.1 million, and a net loss of approximately $0.9 million, along with cash position of $6.5 million. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing results for the three months ended June 30, 2026,\" which is the hallmark of an earnings release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T02:18:47.848722+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27278,"accession_number":"0001683168-26-006077","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (three months ended June 30, 2026). The press release (Exhibit 99.1) reports royalty revenue of approximately $0.7 million, R\u0026D expenses of $0.6 million, G\u0026A expenses of $1.1 million, and a net loss of approximately $0.9 million, along with cash position of $6.5 million. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing results for the three months ended June 30, 2026,\" which is the hallmark of an earnings release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T02:18:47.848722+00:00","company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","filing_date":"2026-08-07"}]}